Single User License
INR 129000
Site License
INR 258000
Corporate User License
INR 387000

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Pancreatitis-Pipeline Review, H1 2017

Pancreatitis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9180IDB
  • |
  • Pages: 70
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Pancreatitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis-Pipeline Review, H1 2017, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 13, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pancreatitis-Overview

Pancreatitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pancreatitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pancreatitis-Companies Involved in Therapeutics Development

Angion Biomedica Corp

Atox Bio Ltd

Bharat Serums And Vaccines Ltd

CalciMedica Inc

Cypralis Ltd

Dynavax Technologies Corp

Generon (Shanghai) Corp Ltd

GlaxoSmithKline Plc

LipimetiX Development Inc

Novartis AG

Pharming Group NV

Sun BioPharma Inc

Pancreatitis-Drug Profiles

AB-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2802-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2814-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (recombinant)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-128-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-4620-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DV-1179-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-652-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-180-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2795039-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-6288B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-07-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-2pal18S-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Trypsin for Pancreatitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-20201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulinastatin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Withaferin A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pancreatitis-Dormant Projects

Pancreatitis-Discontinued Products

Pancreatitis-Product Development Milestones

Featured News & Press Releases

Feb 01, 2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis

Jan 05, 2017: CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor

Oct 24, 2016: Sun BioPharma to Present at the Innovation Biotech Showcase on October 26th

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Pancreatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Pancreatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pancreatitis-Pipeline by Angion Biomedica Corp, H1 2017

Pancreatitis-Pipeline by Atox Bio Ltd, H1 2017

Pancreatitis-Pipeline by Bharat Serums And Vaccines Ltd, H1 2017

Pancreatitis-Pipeline by CalciMedica Inc, H1 2017

Pancreatitis-Pipeline by Cypralis Ltd, H1 2017

Pancreatitis-Pipeline by Dynavax Technologies Corp, H1 2017

Pancreatitis-Pipeline by Generon (Shanghai) Corp Ltd, H1 2017

Pancreatitis-Pipeline by GlaxoSmithKline Plc, H1 2017

Pancreatitis-Pipeline by LipimetiX Development Inc, H1 2017

Pancreatitis-Pipeline by Novartis AG, H1 2017

Pancreatitis-Pipeline by Pharming Group NV, H1 2017

Pancreatitis-Pipeline by Sun BioPharma Inc, H1 2017

Pancreatitis-Dormant Projects, H1 2017

Pancreatitis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Angion Biomedica Corp, Atox Bio Ltd, Bharat Serums And Vaccines Ltd, CalciMedica Inc, Cypralis Ltd, Dynavax Technologies Corp, Generon (Shanghai) Corp Ltd, GlaxoSmithKline Plc, LipimetiX Development Inc, Novartis AG, Pharming Group NV, Sun BioPharma Inc


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com